Curis

Yahoo Finance • 11 months ago

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combinati... Full story

Yahoo Finance • 11 months ago

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

LEXINGTON, Mass., Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical dat... Full story

Yahoo Finance • 2 years ago

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass., April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief... Full story

Yahoo Finance • 2 years ago

Q4 2022 Curis Inc Earnings Call

Participants Diantha Duvall; CFO, Treasurer, Assistant Secretary, Principal Financial Officer & Principal Accounting Officer; Curis, Inc. James E. Dentzer; President, CEO & Director; Curis, Inc. Robert E. Martell; Head of Research & Dev... Full story

Yahoo Finance • 2 years ago

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),... Full story

Yahoo Finance • 2 years ago

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief... Full story

Yahoo Finance • 2 years ago

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

LEXINGTON, Mass., July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ: CRIS).   Such investors are advised to contact Robert S. Willoughby at  newactio... Full story

Yahoo Finance • 3 years ago

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., April 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2022, the independent C... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Curis, Inc. – CRIS

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ: CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@p... Full story